Peptide-Based Therapeutics Peptide-based therapeutics can be broadly categorized into two categories that are based on their chief mechanism of action: immunogenic or tolerogenic
In aged animal models, growth hormone secretion is typically reduced by 50-70% compared to young adult levels, contributing to many of the physiological changes associated with aging including alterations in muscle mass, increased adiposity, reduced bone density, modified immune parameters, and decreased tissue repair capacity
Rather than simply fighting infection, the immune system becomes overactive and creates ongoing inflammation that can damage: Joints Muscles Tendons and ligaments Nerves Connective tissues Internal organs This chronic inflammatory response can create persistent pain even when structural imaging looks relatively normal
Need for short-term catheterization (Varies from 5 days to 2 weeks)
Genetics, metabolic health, hormone status, age, lifestyle habits, and overall physiology can all influence peptide pharmacokinetics and clinical outcomes